Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.98 |
| ▸ | HPGD | P15428 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | CLK2 | P49760 | 1/20 | 0.71 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxifloxacin SCHEMBL1883937 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL15472879 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL29414621 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL29356466 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL12015472 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL28408968 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL4774670 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL12156451 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL21783209 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Moxifloxacin SCHEMBL2293939 | 0.99 | KDM4E (0.97) | KDM4EALDH1A1HPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34661 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137766-A1 | LIPOSOME FORMULATIONS FOR TREATMENT OF ACTIVE TUBERCULOSIS | ARCHIVEL FARMA S L (ES) | 2026-05-21 | — | — | US | claimed |
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| US-12631653-B2 | Methods for diagnosing and treating uveitis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-19 | — | — | US | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| CN-122017236-A | TB and NTM combined detection system and method based on multichannel immunodetection | 恒燊中医科技(上海)有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2001010408-A2 | AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING MOXIFLOXACIN OR SALTS THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2001-02-15 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| WO-2000059475-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-2000032196-A2 | INHIBITORS OF MULTIDRUG TRANSPORTERS | INFLUX, INC. (US) | 2000-06-08 | — | — | WO | claimed |
| WO-2000027398-A1 | PHARMACEUTICAL MOXIFLOXACIN PREPARATION | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | claimed |
| WO-2000018386-A2 | ANTIBIOTIC COMPOSITIONS FOR TREATMENT OF THE EYE, EAR AND NOSE | ALCON LABORATORIES, INC. (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0971691-A2 | COMBINATION PREPARATION FOR ORALLY ADMINISTERED ANTIBIOTICS | Lindopharm Gmbh (DE) | 2000-01-19 | — | — | EP | claimed |
| WO-1998036732-A2 | COMBINATION PREPARATION FOR ORALLY ADMINISTERED ANTIBIOTICS | LINDOPHARM GMBH (DE) | 1998-08-27 | — | — | WO | claimed |
| US-5607942-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | claimed |